Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD1 | Q15139 | 20/20 | 0.61 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | PRKCA | P17252 | 1/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1424391 | 0.93 | PRKD1 (0.71) | PRKD1PRKD2ADRB1PRKCAPRKCD | |
| SCHEMBL1424009 | 0.92 | PRKD1 (0.73) | PRKD1PRKD2ADRB1PRKCAPRKCD | |
| SCHEMBL1424007 | 0.90 | PRKD1 (0.63) | PRKD1PRKD2ADRB1PRKCAPRKCD | |
| SCHEMBL1424169 | 0.88 | PRKD1 (0.55) | PRKD1PRKD2ADRB1PRKCAPRKCD | |
| SCHEMBL1424138 | 0.88 | PRKD1 (0.56) | PRKD1PRKD2ADRB1PRKCAPRKCD | |
| SCHEMBL1424160 | 0.87 | PRKD1 (0.74) | PRKD1PRKD2ADRB1PRKCAPRKCD | |
| SCHEMBL1424024 | 0.85 | PRKD1 (0.52) | PRKD1PRKD2ADRB1PRKCAPRKCD | |
| SCHEMBL1424086 | 0.84 | PRKD1 (0.62) | PRKD1PRKD2ADRB1PRKCAPRKCD | |
| SCHEMBL1424664 | 0.83 | PRKD1 (0.51) | PRKD1PRKD2ADRB1PRKCAPRKCD | |
| SCHEMBL1423942 | 0.83 | PRKD1 (0.80) | PRKD1PRKD2ADRB1PRKCAPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142685-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120142685-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120142685-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| EP-2144909-B1 | [2,6]NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| EP-2144909-B1 | [2,6]NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| EP-2144909-A1 | [2, 6]NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS | Novartis Ag (CH) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008122615-A1 | [2, 6] NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122615-A1 | [2, 6] NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142685-A1 | ORGANIC COMPOUNDS | MARK1, PKN1, MARK2 | PRKD1 164/4885PRKD2 158/4885ADRB1 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.